Special Report
These inexpensive stocks can often bring the potential for substantial rewards for investors who know where to look. But unfortunately, identifying opportunities of significant quality can sometimes be difficult.
When evaluating undervalued stocks trading for under $10, it’s important to look both at the potential for the underlying business as well as industry trends. A careful assessment of the company’s potential upside must be weighed against the risk involved in any stock selection.
What follows is a list of 5 of the most attractive undervalued stocks trading for under $10 that you should consider now. As always, be sure to do your own due diligence before investing in any stock to make sure it’s right for your financial situation and that it is consistent with your acceptable level of risk.
Top Stock #5: Canada Nickel Company Inc. (TSXV: CNC)
Southwestern Energy Company (NYSE: SWN) is an exploration and production company focusing on natural gas. The company has recently benefited from the resurgence in the broader hydrocarbon sector.
The company operates through two segments, Exploration and Production, and Marketing. The company focuses on the development of unconventional natural gas and oil reservoirs located in Pennsylvania, West Virginia, Ohio, and Louisiana.
It also engages in the marketing and transportation of natural gas, oil, and NGLs. The company serves LNG exporters, energy companies, utilities, and industrial purchasers of natural gas.
In June 2022, the company authorized a $1 billion share repurchase program that can continue through the end of 2023. In the first quarter, Southwestern reported net income of $1.9 billion, swinging from a net loss of $2.7 billion in the year-ago quarter.
Top Stock #2: Sibanye Stillwater Limited (NYSE: SBSW)
Sibanye Stillwater Limited (NYSE: SBSW) is a South African precious metal mining company that produces products such as gold and platinum. A growing global economy benefits the firm as its products are used in industrial and manufacturing processes.
The company owns the East Boulder and Stillwater mines located in Montana, the United States; and Columbus metallurgical complex, which smelts the material mined to produce PGM-rich filter cake, as well as conducts PGM recycling activities.
The company is also involved in the Kroondal, Rustenburg, Marikana, and Platinum Mile operations situated in South Africa; Mimosa located on the southern portion in Zimbabwe; the Driefontein, Kloof, Rand Refinery, and Cooke surface operations located on the West Rand of the Witwatersrand Basin; and the Beatrix situated in the southern Free State.
In addition, it owns an interest in surface tailings retreatment facilities; the Marathon PGM project in Ontario, Canada; the Altar and Rio Grande copper gold projects in the Andes in north-west Argentina; the Hoedspruit; and the Burnstone and southern Free State gold projects in South Africa.
According to analysts’ consensus target of $9.50, Sibanye Stillwater Limited has a forecasted upside of just over 60% from its share price of $5.93 as of this writing.
Top Stock #3: Nokia Corporation (NYSE: NOK)
Nokia (NYSE: NOK) is the world’s third-largest provider of telecommunications equipment.
Service providers (such as AT&T and Vodaphone) as well as enterprises and partners worldwide trust Nokia to deliver secure, reliable and sustainable networks.
The company operates through four segments: Network Infrastructure, Mobile Networks, Cloud and Network Services, and Nokia Technologies. It offers products and services for radio access networks and microwave radio links for transport networks, and solutions for network management, as well as network planning, optimization, network deployment, and technical support services.
The consensus price target among analysts for Nokia is $6.24, representing a forecasted upside of 55% from its current share price of $4.02 as of this writing.
Artisan International Value Fund said the following about Nokia in its second quarter 2023 investor letter: “At some point, the ever-increasing need for wire and wireless bandwidth will force service providers to increase investment. In addition, Nokia’s market share is improving due to geopolitical changes and improved market competitiveness.”
Top Stock #4: SCYNEXIS, INC (Nasdaq: SCYX)
SCYNEXIS, Inc. (Nasdaq: SCYX), a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC.
The company’s lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
The U.S. Food and Drug Administration (FDA) approved the first representative of this antifungal class BREXAFEMME® (ibrexafungerp tablets) in June 2021, for its first indication in vulvovaginal candidiasis (VVC), followed by a second indication in November 2022, for reduction in the incidence of recurrent VVC.
Late-stage clinical investigation of ibrexafungerp for the treatment of life-threatening invasive fungal infections is ongoing. Additional assets in the novel “fungerp” class of antifungals are currently in the pre-clinical and discovery phase, including the compound SCY-247.
SCYNEXIS, Inc. has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co, Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp.
SCYNEXIS has received a consensus rating of “Buy” – based on 4 buy ratings, no hold ratings and no sell ratings. According to analysts’ consensus price target of $11.40, the company’s shares have a forecasted upside of 231% from the current price of $3.41 as of this writing.
Top Stock #5: Quipt Home Medical Corp (Nasdaq: QIPT)
Quipt Home Medical Corp. (Nasdaq: QIPT) is a medical devices company that sells products such as masks, beds, and nebulizers.
The company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions.
The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management.
The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.
In August 2023, the company reported strong operational performance with record third quarter fiscal 2023 results, posting revenue growth of 64% and adjusted EBITDA growth of 80%.
Two independent analysts have issued “buy” ratings on the company’s shares with a consensus share price target of $10.00. That represents a forecasted upside of 76.1% from its current price of $5.68 as of this writing.